Report of Foreign Issuer (6-k)
September 01 2020 - 4:01PM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
dated
September 1, 2020
Commission
File Number 0-51504
GENETIC
TECHNOLOGIES LIMITED
(Exact
Name as Specified in its Charter)
N/A
(Translation
of Registrant’s Name)
60-66
Hanover Street
Fitzroy
Victoria
3065 Australia
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F [X] Form 40-F [ ]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
[ ] No [X]
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not
applicable.
Since
April, 2020, Genetic Technologies Limited (the “Company”) has raised an aggregate of $16.37 million through offerings
of its American Depositary Shares. As a result, the Company believes that, as of the date of this filing, it has US GAAP stockholders’
equity in excess of $2.5 million. Accordingly, the Company has received notification from The Nasdaq Stock Market LLC (“Nasdaq”)
indicating that the Nasdaq Hearings Panel has determined that the Company has regained compliance with the minimum stockholders’
equity requirement, as set forth in Listing Rule 5550(b)(1) (the “Equity Rule”), for continued listing on The Nasdaq
Capital Market and that Nasdaq has closed its listing review.
As
previously disclosed, on March 13, 2020, the Company received a determination letter from Nasdaq indicating that the Company’s
American Depositary Shares were potentially subject to delisting from The Nasdaq Capital Market as the Company did not comply
with the Equity Rule, which requires the Company to have a minimum of $2.5 million in stockholders’ equity or market value
of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal
year or two of the last three most recently completed fiscal years. The Nasdaq Hearings Panel on May 12, 2020, granted the Company
an extension through September 9, 2020, to regain compliance. As noted above, this matter is now closed.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
September 1, 2020
|
GENETIC
TECHNOLOGIES LIMITED
|
|
|
|
By:
|
/s/
Justyn Stedwell
|
|
Name:
|
Justyn
Stedwell
|
|
Title:
|
Company
Secretary
|
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Apr 2023 to Apr 2024